| abstract |
The present invention provides compositions and methods for administering oxybutynin and reducing both the incidence and / or severity of adverse drug experiences associated with oxybutynin therapy. In one aspect, these compositions and methods provide a lower plasma concentration of oxybutynin metabolites such as N-deethyloxybutynin, which is presumed to contribute at least in part to some of the adverse experiences with the drug, while maintaining a Plasma concentration of oxybutynin sufficient to benefit a subject with oxybutynin therapy. The invention also proportions isomers of oxybutynin and its metabolites that satisfy those characteristics of minimized incidence and / or severity of adverse experiences with the drug, and maintenance of beneficial and effective therapy for the overactive bladder. |